Current Value
$7.851 Year Return
Current Value
$7.851 Year Return
Finnhub
-- Single Pivotal Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period ---- Pioneering Patient-Centric Dosing Flexibility in...
Finnhub
BOSTON - Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650 shares of...
Yahoo
BOSTON, January 03, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650 shares of Astria’s common stock on January 2, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
Finnhub
ASTRIA THERAPEUTICS, INC. 2022 INDUCEMENT STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2022 Inducement Stock Incentive Plan of Astria...
Yahoo
BOSTON, December 11, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These final results demonstrated reduction in the mean mon
Yahoo
BOSTON, December 10, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for STAR-0310, a monoclonal antibody OX40 antagonist, the company is developing as a potential treatment for atopic dermatitis (AD) and potentially other indications. A Phase 1a trial of STAR-0310 in
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KYMR | 47.15% | $2.61B | +48.13% | 0.00% |
KALV | 43.92% | $407.70M | -33.79% | 0.00% |
ACLX | 42.99% | $3.62B | +26.01% | 0.00% |
CRNX | 42.94% | $3.38B | +0.77% | 0.00% |
OPEN | 41.62% | $1.10B | -48.84% | 0.00% |
NOVT | 39.97% | $5.30B | -5.64% | 0.00% |
PLRX | 39.87% | $705.90M | -29.74% | 0.00% |
YMAB | 39.63% | $276.80M | -36.16% | 0.00% |
ARVN | 39.54% | $1.21B | -51.68% | 0.00% |
NVRI | 39.49% | $693.17M | +6.40% | 0.00% |
BNT | 39.46% | $7.40B | +48.44% | 0.00% |
SNDX | 39.24% | $1.11B | -39.00% | 0.00% |
ABCL | 39.06% | $868.38M | -43.35% | 0.00% |
BEAM | 38.64% | $1.94B | -0.26% | 0.00% |
AMWD | 38.61% | $1.22B | -12.05% | 0.00% |
FATE | 37.73% | $142.37M | -71.13% | 0.00% |
RCKT | 37.64% | $1.09B | -60.97% | 0.00% |
SXI | 37.50% | $2.25B | +25.62% | 0.64% |
ROCK | 37.35% | $1.89B | -23.99% | 0.00% |
EWTX | 37.25% | $2.53B | +175.75% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MESO | -0.07% | $1.94B | +869.19% | 0.00% |
AJG | 0.09% | $73.89B | +24.83% | 0.81% |
PSQH | 0.09% | $195.63M | -11.07% | 0.00% |
ARLP | -0.13% | $3.59B | +27.05% | 10.00% |
VNET | 0.13% | $1.48B | +136.97% | 0.00% |
PRPO | -0.21% | $9.12M | -8.35% | 0.00% |
DUK | 0.22% | $84.25B | +13.77% | 3.80% |
LMT | 0.28% | $115.40B | +5.94% | 2.62% |
LPTH | -0.28% | $121.37M | +131.82% | 0.00% |
COR | -0.30% | $46.56B | +9.10% | 0.86% |
NGL | 0.34% | $706.27M | +4.90% | 0.00% |
MVO | 0.36% | $93.84M | -29.04% | 16.05% |
MNR | -0.45% | $1.82B | +2.15% | 18.25% |
PEP | 0.63% | $201.05B | -12.34% | 3.61% |
VSTA | -0.64% | $188.40M | -44.05% | 0.00% |
MMC | 0.65% | $106.22B | +8.97% | 1.41% |
FUBO | -0.71% | $1.35B | +58.33% | 0.00% |
XGN | 0.72% | $53.97M | +48.54% | 0.00% |
PHG | 0.79% | $24.03B | +13.81% | 0.00% |
EW | 0.81% | $41.20B | -6.15% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HUSA | -14.40% | $22.51M | +5.52% | 0.00% |
PULM | -14.03% | $22.43M | +245.04% | 0.00% |
QNTM | -8.70% | $6.35M | -94.08% | 0.00% |
K | -8.46% | $28.11B | +49.49% | 2.78% |
CBOE | -8.31% | $20.30B | +3.74% | 1.22% |
VZ | -7.50% | $161.40B | -1.54% | 6.99% |
BEST | -7.45% | $31.77M | +9.35% | 0.00% |
UUU | -7.19% | $5.41M | +48.10% | 0.00% |
STG | -6.85% | $29.30M | -34.12% | 0.00% |
BTCT | -6.67% | $23.92M | +5.78% | 0.00% |
DOGZ | -6.56% | $562.95M | +1,227.93% | 0.00% |
TKO | -6.32% | $11.51B | +86.97% | 0.00% |
VIRT | -5.87% | $3.17B | +96.96% | 2.59% |
FLUT | -5.71% | $45.86B | +33.85% | 0.00% |
CME | -5.45% | $83.72B | +14.49% | 4.46% |
OXBR | -5.34% | $24.62M | +287.75% | 0.00% |
NOC | -5.34% | $70.11B | +1.38% | 1.67% |
HRL | -5.09% | $16.41B | -3.83% | 3.81% |
MCK | -4.66% | $75.55B | +20.73% | 0.45% |
TCTM | -4.58% | $2.68M | -74.53% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 52.25% | $270.72M | 0% |
XPH | 50.66% | $159.10M | 0.35% |
XBI | 50.53% | $5.97B | 0.35% |
IWC | 49.07% | $962.03M | 0.6% |
IBB | 48.44% | $6.29B | 0.45% |
PTH | 48.19% | $116.47M | 0.6% |
PBE | 47.71% | $249.05M | 0.58% |
GNOM | 47.33% | $67.37M | 0.5% |
IWO | 47.06% | $12.82B | 0.24% |
ARKG | 46.64% | $1.12B | 0.75% |
VTWO | 46.46% | $12.56B | 0.1% |
IWM | 46.37% | $72.20B | 0.19% |
EFAA | 45.85% | $102.96M | 0% |
ISCG | 45.46% | $650.49M | 0.06% |
PSC | 44.98% | $757.78M | 0.38% |
SMMD | 44.71% | $1.39B | 0.15% |
ESML | 44.69% | $1.92B | 0.17% |
NUSC | 44.46% | $1.23B | 0.31% |
PRFZ | 44.42% | $2.54B | 0.39% |
GSSC | 44.40% | $537.26M | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
JUCY | 0.38% | $299.79M | 0.6% |
KRBN | -0.57% | $198.93M | 0.85% |
USCI | 0.66% | $201.05M | 1.07% |
CORN | -0.89% | $65.53M | 0.2% |
SEIX | 1.31% | $308.05M | 0.62% |
CANE | 1.32% | $11.58M | 0.29% |
IVOL | 1.57% | $457.45M | 1.02% |
BSSX | 1.67% | $63.43M | 0.18% |
AGZD | -1.94% | $148.43M | 0.23% |
BSMW | 2.31% | $91.41M | 0.18% |
IBTF | 2.41% | $2.24B | 0.07% |
TBIL | 2.77% | $4.83B | 0.15% |
IBMN | 2.99% | $484.25M | 0.18% |
ULST | 3.03% | $549.72M | 0.2% |
TBLL | 3.11% | $1.98B | 0.08% |
XHLF | 3.80% | $943.05M | 0.03% |
SHYD | 3.84% | $311.16M | 0.35% |
SOYB | -4.16% | $25.86M | 0.22% |
BCI | 4.23% | $1.37B | 0.26% |
XONE | 4.40% | $571.79M | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -24.39% | $195.31M | 0.85% |
TAIL | -16.10% | $65.23M | 0.59% |
UNG | -13.20% | $852.04M | 1.06% |
TPMN | -12.24% | $41.98M | 0.65% |
USDU | -11.27% | $396.64M | 0.5% |
CTA | -9.70% | $553.08M | 0.76% |
WEAT | -9.57% | $121.95M | 0.28% |
UUP | -9.22% | $636.64M | 0.77% |
DBA | -7.88% | $817.28M | 0.93% |
SOYB | -4.16% | $25.86M | 0.22% |
AGZD | -1.94% | $148.43M | 0.23% |
CORN | -0.89% | $65.53M | 0.2% |
KRBN | -0.57% | $198.93M | 0.85% |
JUCY | 0.38% | $299.79M | 0.6% |
USCI | 0.66% | $201.05M | 1.07% |
SEIX | 1.31% | $308.05M | 0.62% |
CANE | 1.32% | $11.58M | 0.29% |
IVOL | 1.57% | $457.45M | 1.02% |
BSSX | 1.67% | $63.43M | 0.18% |
BSMW | 2.31% | $91.41M | 0.18% |